G
Giovanni Barosi
Researcher at University of Pavia
Publications - 352
Citations - 21433
Giovanni Barosi is an academic researcher from University of Pavia. The author has contributed to research in topics: Myelofibrosis & Essential thrombocythemia. The author has an hindex of 69, co-authored 334 publications receiving 19225 citations.
Papers
More filters
Journal ArticleDOI
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Claire N. Harrison,Jean-Jacques Kiladjian,Haifa Kathrin Al-Ali,Heinz Gisslinger,Roger J. Waltzman,Viktoriya Stalbovskaya,Mari McQuitty,Deborah S. Hunter,Richard S. Levy,Laurent Knoops,Francisco Cervantes,Alessandro M. Vannucchi,Tiziano Barbui,Giovanni Barosi +13 more
TL;DR: Continuous ruxolitinib therapy, as compared with the best available therapy, was associated with marked and durable reductions in splenomegaly and disease-related symptoms, improvements in role functioning and quality of life, and modest toxic effects.
Journal ArticleDOI
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Francisco Cervantes,Brigitte Dupriez,Arturo Pereira,Francesco Passamonti,John T. Reilly,Enrica Morra,Alessandro M. Vannucchi,Ruben A. Mesa,Jean Loup Demory,Giovanni Barosi,Elisa Rumi,Ayalew Tefferi +11 more
TL;DR: In 409 patients with assessable metaphases, cytogenetic abnormalities were associated with shorter survival, but their independent contribution to prognosis was restricted to patients in the intermediate-risk groups.
Journal ArticleDOI
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
Ayalew Tefferi,Juergen Thiele,Attilio Orazi,Hans Michael Kvasnicka,Tiziano Barbui,Curtis A. Hanson,Giovanni Barosi,Srdan Verstovsek,Gunnar Birgegård,Ruben A. Mesa,John T. Reilly,Heinz Gisslinger,Alessandro M. Vannucchi,Francisco Cervantes,Guido Finazzi,Ronald Hoffman,D. Gary Gilliland,Clara D. Bloomfield,James W. Vardiman +18 more
TL;DR: In this paper, the authors proposed a revision of the current World Health Organization (WHO) diagnostic criteria for polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), which was subsequently presented by an international expert panel of pathologists and clinical investigators in myeloproliferative disorders.
Journal ArticleDOI
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui,Giovanni Barosi,Gunnar Birgegård,Francisco Cervantes,Guido Finazzi,Martin Griesshammer,Claire N. Harrison,Hans Carl Hasselbalch,Rüdiger Hehlmann,Ronald Hoffman,Jean-Jacques Kiladjian,Kröger N,Ruben A. Mesa,Mary Frances McMullin,Animesh Pardanani,Francesco Passamonti,Alessandro M. Vannucchi,Andreas Reiter,Richard T. Silver,Srdan Verstovsek,Ayalew Tefferi +20 more
TL;DR: A review of critical concepts and recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition, first- and second-line therapy, and therapy for special issues are presented.
Journal ArticleDOI
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.
Alessandro M. Vannucchi,Elisabetta Antonioli,Paola Guglielmelli,Alessandro Rambaldi,Giovanni Barosi,Roberto Marchioli,Rosa Maria Marfisi,Guido Finazzi,Vittoria Guerini,Fabrizio Fabris,Maria Luigia Randi,Valerio De Stefano,Sabrina Caberlon,Agostino Tafuri,Marco Ruggeri,Giorgina Specchia,Vincenzo Liso,Edoardo Rossi,Enrico Pogliani,Luigi Gugliotta,Alberto Bosi,Tiziano Barbui +21 more
TL;DR: It is concluded that JAK2 617V>F homozygosity identifies PV or ET patients with a more symptomatic myeloproliferative disorder and is associated with a higher risk of major cardiovascular events in patients with ET.